Literature DB >> 26264708

CFTR inactivation by lentiviral vector-mediated RNA interference and CRISPR-Cas9 genome editing in human airway epithelial cells.

Jessica Bellec, Marc Bacchetta, Davide Losa, Ignacio Anegon, Marc Chanson1, Tuan Huy Nguyen.   

Abstract

BACKGROUND: Polarized airway epithelial cell cultures modelling Cystic Fibrosis Transmembrane conductance Regulator (CFTR) defect are crucial for CF and biomedical research. RNA interference has proven its value to generate knockdown models for various pathologies. More recently, genome editing using CRISPR-Cas9 artificial endonuclease was a valuable addition to the toolbox of gene inactivation.
METHODS: Calu-3 cells and primary HAECs were transduced with HIV-1-derived lentiviral vectors (LVV) encoding small hairpin RNA (shRNA) sequence or CRISPR-Cas9 components targeting CFTR alongside GFP. After sorting of GFP-positive cells, CFTR expression was measured by RT-qPCR and Western blot in polarized or differentiated cells. CFTR channel function was assessed in Ussing chambers. Il-8 secretion, proliferation and cell migration were also studied in transduced cells.
RESULTS: shRNA interference and CRISPRCas9 strategies efficiently decreased CFTR expression in Calu-3 cells. Strong CFTR knockdown was confirmed at the functional level in CRISPR-Cas9-modified cells. CFTR-specific shRNA sequences did not reduce gene expression in primary HAECs, whereas CRISPR-Cas9-mediated gene modification activity was correlated with a reduction of transepithelial secretion and response to a CFTR inhibitor. CFTR inactivation in the CRISPR-Cas9-modified Calu-3 cells did not affect migration and proliferation but slightly increased basal interleukin-8 secretion.
CONCLUSION: We generated CFTR inactivated cell lines and demonstrated that CRISPR-Cas9 vectorised in a single LVV efficiently promotes CFTR inactivation in primary HAECs. These results provide a new protocol to engineer CF primary epithelia with their isogenic controls and pave the way for manipulation of CFTR expression in these cultures.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26264708     DOI: 10.2174/1566523215666150812115939

Source DB:  PubMed          Journal:  Curr Gene Ther        ISSN: 1566-5232            Impact factor:   4.391


  16 in total

1.  A Protocol for the Production of Integrase-deficient Lentiviral Vectors for CRISPR/Cas9-mediated Gene Knockout in Dividing Cells.

Authors:  Sriram Vijayraghavan; Boris Kantor
Journal:  J Vis Exp       Date:  2017-12-12       Impact factor: 1.355

Review 2.  Animal and model systems for studying cystic fibrosis.

Authors:  Bradley H Rosen; Marc Chanson; Lara R Gawenis; Jinghua Liu; Aderonke Sofoluwe; Alice Zoso; John F Engelhardt
Journal:  J Cyst Fibros       Date:  2017-09-19       Impact factor: 5.482

3.  Surface Hydration Protects Cystic Fibrosis Airways from Infection by Restoring Junctional Networks.

Authors:  Juliette L Simonin; Alexandre Luscher; Davide Losa; Mehdi Badaoui; Christian van Delden; Thilo Köhler; Marc Chanson
Journal:  Cells       Date:  2022-05-09       Impact factor: 7.666

Review 4.  Cystic fibrosis: a model system for precision medicine.

Authors:  Stacey L Martiniano; Scott D Sagel; Edith T Zemanick
Journal:  Curr Opin Pediatr       Date:  2016-06       Impact factor: 2.856

Review 5.  Epithelial Anion Transport as Modulator of Chemokine Signaling.

Authors:  Andrea Schnúr; Péter Hegyi; Simon Rousseau; Gergely L Lukacs; Guido Veit
Journal:  Mediators Inflamm       Date:  2016-06-12       Impact factor: 4.711

Review 6.  Therapeutic gene editing: delivery and regulatory perspectives.

Authors:  Gayong Shim; Dongyoon Kim; Gyu Thae Park; Hyerim Jin; Soo-Kyung Suh; Yu-Kyoung Oh
Journal:  Acta Pharmacol Sin       Date:  2017-04-10       Impact factor: 6.150

7.  Highly efficient gene inactivation by adenoviral CRISPR/Cas9 in human primary cells.

Authors:  Olaf Voets; Frans Tielen; Edo Elstak; Julian Benschop; Max Grimbergen; Jan Stallen; Richard Janssen; Andre van Marle; Christian Essrich
Journal:  PLoS One       Date:  2017-08-11       Impact factor: 3.240

8.  Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR/Cas9-Mediated Gene Editing.

Authors:  Pavel I Ortinski; Bernadette O'Donovan; Xiaoyu Dong; Boris Kantor
Journal:  Mol Ther Methods Clin Dev       Date:  2017-04-19       Impact factor: 6.698

9.  Efficient Generation of Myostatin Knock-Out Sheep Using CRISPR/Cas9 Technology and Microinjection into Zygotes.

Authors:  M Crispo; A P Mulet; L Tesson; N Barrera; F Cuadro; P C dos Santos-Neto; T H Nguyen; A Crénéguy; L Brusselle; I Anegón; A Menchaca
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 10.  Personalized or Precision Medicine? The Example of Cystic Fibrosis.

Authors:  Fernando A L Marson; Carmen S Bertuzzo; José D Ribeiro
Journal:  Front Pharmacol       Date:  2017-06-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.